Jingwu Zang (I-Mab)
AbbVie jumps into CD47 game, engineers $3B deal with ambitious Chinese player
Gilead’s $4.9 billion bet on Forty Seven evidently triggered a rush among Big Pharma to look for their own drug that targets the CD47 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
